Study of Magrolimab and Pembrolizumab in Relapsed or Refractory Classic Hodgkin Lymphoma

NCT04788043 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

8

Enrollment

OTHER

Sponsor class

Conditions

Hodgkin Lymphoma
Classic Hodgkin Lymphoma
Relapsed Classical Hodgkin Lymphoma
Refractory Classic Hodgkin Lymphoma

Interventions

DRUG: Magrolimab
DRUG: Pembrolizumab
PROCEDURE: PET/CT

Sponsor

Stanford University

Collaborators

[object Object]